Lenvatinib has the ability to treat some hepatocellular carcinomas. However, it should be noted that the drug must be used under the strict supervision of clinicians, and unauthorized use of the drug is prohibited. Lenvatinib has the effect of inhibiting tyrosine kinase receptor, which can inhibit the abnormal proliferation and differentiation of some tumor cells, and can be used in the treatment of unresectable hepatocellular carcinoma that has not received systemic systemic treatment before. The drug belongs to molecular targeted drugs, and its use must be carried out by physicians with experience in the use of drugs after a comprehensive assessment of the condition, and attention should be paid to the detection of vital signs and blood routine and other items during the use of the drug. If adverse reactions such as severe hypertension, nephrotic syndrome, severe hepatic or renal impairment, severe cardiac impairment, arterial thromboembolism, hemorrhage, gastrointestinal perforation, or severe cardiac arrhythmia occur during the administration of the drug, it is necessary to immediately discontinue the use of the drug and permanently prohibit the use of this product. The product is contraindicated for those who are allergic to the product and the ingredients contained in it, pregnant and lactating women. Lenvatinib should be used under the guidance of a professional doctor and unauthorized use of the drug is prohibited.